ESC Premium Access

Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial

Congress Presentation

About the speaker

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)
47 presentations

7 more presentations in this session

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.

Speaker: Doctor G. Ferrannini (Stockholm, SE)


Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis

Speaker: Professor H. Colhoun (Edinburgh, GB)


Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition

Speaker: Doctor H. Kondo (Yufu City, JP)


Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME

Speaker: Professor S. Verma (Toronto, CA)


Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Speaker: Professor H. Heerspink (Groningen, NL)


Access the full session

Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Speakers: Professor N. Marx, Doctor G. Ferrannini, Professor H. Colhoun, Doctor H. Kondo, Professor S. Verma...

About the event


ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb